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NaF PET/CT for response assessment of prostate cancer bone metastases
treated with single fraction stereotactic ablative body radiotherapy
Abstract
Introduction: In prostate cancer patients, imaging of bone metastases is enhanced through the use of
sodium fluoride positron emission tomography (18F-NaF PET/CT). This imaging technique shows areas
of enhanced osteoblastic activity and blood flow. In this work, 18F-NaF PET/CT was investigated for
response assessment to single fraction stereotactic ablative body radiotherapy (SABR) to bone
metastases in prostate cancer patients. Methods: Patients with bone metastases in a prospective trial
treated with single fraction SABR received a 18F-NaF PET/CT scan prior to and 6 months post-SABR. The
SUVmax in the tumour was determined and the difference between before and after SABR determined.
The change in uptake in the non-tumour bone was also measured as a function of the received SABR
dose. Results: Reduction in SUVmax was observed in 29 of 33 lesions 6 months after SABR (mean
absolute decrease in SUVmax 17.7, 95% CI 25.8 to - 9.4, p = 0.0001). Of the three lesions with increased
SUVmax post-SABR, two were from the same patient and located in the vertebral column. Both were
determined to be local progression in addition to one fracture. The third lesion (in a rib) was shown to be
controlled locally but suffered from a fracture at 24 months. Progression adjacent to the treated volume
was observed in two patients. The non-tumour bone irradiated showed increased loss in uptake with
increasing dose, with a median loss in uptake of 23.3% for bone receiving 24 Gy. Conclusion: 18F-NaF
PET/CT for response assessment of bone metastases to single fraction SABR indicates high rates of
reduction of osteoblastic activity in the tumour and non-tumour bone receiving high doses. The
occurrence of marginal recurrence indicates use of larger clinical target volumes may be warranted in
treatment of bone metastases. Trial registration: POPSTAR, 'Pilot Study of patients with Oligometastases
from Prostate cancer treated with STereotactic Ablative Radiotherapy', Universal Trial Number
U1111-1140-7563, Registered 17th April 2013.

Disciplines
Engineering | Science and Technology Studies

Publication Details
Hardcastle, N., Hofman, M. S., Lee, C., Callahan, J., Selbie, L., Foroudi, F., Shaw, M., Chander, S., Lim, A.,
Chesson, B., Murphy, D. G., Kron, T. & Siva, S. (2019). NaF PET/CT for response assessment of prostate
cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy. Radiation
Oncology, 14 (1), 164-1-164-8.

Authors
Nicholas G. Hardcastle, Michael S. Hofman, Ching-Yu Lee, Jason Callahan, Lisa Selbie, Farshad Foroudi,
Mark Shaw, Sarat Chander, Andrew Lim, Brent Chesson, Declan G. Murphy, Tomas Kron, and Shankar Siva

This journal article is available at Research Online: https://ro.uow.edu.au/eispapers1/3168

Hardcastle et al. Radiation Oncology
(2019) 14:164
https://doi.org/10.1186/s13014-019-1359-0

RESEARCH

Open Access

NaF PET/CT for response assessment of
prostate cancer bone metastases treated
with single fraction stereotactic ablative
body radiotherapy
Nicholas Hardcastle1,7* , Michael S. Hofman2, Ching-Yu Lee1, Jason Callahan2, Lisa Selbie3, Farshad Foroudi4,
Mark Shaw3, Sarat Chander3, Andrew Lim5, Brent Chesson5, Declan G. Murphy6,8, Tomas Kron1,7,8 and
Shankar Siva3,8

Abstract
Introduction: In prostate cancer patients, imaging of bone metastases is enhanced through the use of sodium
fluoride positron emission tomography (18F-NaF PET/CT). This imaging technique shows areas of enhanced
osteoblastic activity and blood flow. In this work, 18F-NaF PET/CT was investigated for response assessment to
single fraction stereotactic ablative body radiotherapy (SABR) to bone metastases in prostate cancer patients.
Methods: Patients with bone metastases in a prospective trial treated with single fraction SABR received a 18F-NaF
PET/CT scan prior to and 6 months post-SABR. The SUVmax in the tumour was determined and the difference
between before and after SABR determined. The change in uptake in the non-tumour bone was also measured as
a function of the received SABR dose.
Results: Reduction in SUVmax was observed in 29 of 33 lesions 6 months after SABR (mean absolute decrease in
SUVmax 17.7, 95% CI 25.8 to − 9.4, p = 0.0001). Of the three lesions with increased SUVmax post-SABR, two were from
the same patient and located in the vertebral column. Both were determined to be local progression in addition to
one fracture. The third lesion (in a rib) was shown to be controlled locally but suffered from a fracture at 24 months.
Progression adjacent to the treated volume was observed in two patients. The non-tumour bone irradiated showed
increased loss in uptake with increasing dose, with a median loss in uptake of 23.3% for bone receiving 24 Gy.
Conclusion: 18F-NaF PET/CT for response assessment of bone metastases to single fraction SABR indicates high
rates of reduction of osteoblastic activity in the tumour and non-tumour bone receiving high doses. The occurrence of
marginal recurrence indicates use of larger clinical target volumes may be warranted in treatment of bone metastases.
Trial registration: POPSTAR, ‘Pilot Study of patients with Oligometastases from Prostate cancer treated with
STereotactic Ablative Radiotherapy’, Universal Trial Number U1111-1140-7563, Registered 17th April 2013.
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Background
Prostate cancer represents a major cancer burden in
men, representing the most common male cancer diagnosis [1]. Prostate cancer staging determines appropriate
treatment at initial presentation and during disease progression and makes use of various medical imaging techniques. The most probable site of distant metastases in
prostate cancer is bone, thus imaging techniques used
for visualization of prostate metastases must be able to
accurately visualize sites of bone disease [2]. This is particularly so with increasing interest in metastasisdirected therapy (MDT) for oligometastatic prostate cancer [3–5]. The standard imaging for determination of
prostate cancer bone metastases has been whole body
bone scan with 2D scintigraphy or single photon emission computed tomography (SPECT) approaches, using
99m
Tc methylene diphosphonate [6, 7]. These tracers are
taken up at sites of high osteoblastic activity representing bone turnover. The tumour burden as represented
on bone scans can be quantified into a bone scan index
(BSI), which has been shown as an independent prognostic marker for survival [8, 9]. Bone scans have many
limitations however, such as poor anatomical correlation
and low specificity and sensitivity [10, 11].
Prior to use of 99mTc MDP, 18F sodium fluoride
18
( F-NaF) was used for planar scintigraphy [12]. In recent years however 18F-NaF has been used for PET/CT
acquisition, which allows high spatial resolution 3D imaging of osteoblastic activity and blood flow [13–15].
18
F-NaF has been shown to have improved sensitivity
and specificity for prostate cancer metastases, compared
with 99mTc MDP [10], although improvements through
use of quantitative SPECT have recently suggested consistent standardised uptake value (SUV) between the two
modalities for prostate and breast bone metastases [16].
In the context of oligometastatic prostate cancer, 18FNaF PET/CT imaging facilitates high quality detection and
visualization of skeletal metastases which may be suitable
for local MDT such as stereotactic ablative body radiotherapy (SABR). In this study we examine 18F-NaF uptake prior
to and after single fraction SABR to bone metastases in patients enrolled in a prospective clinical trial. We investigate
18
F-NaF uptake in tumour and non-tumour bone, with the
hypothesis that tumour and normal tissue response to
SABR can be assessed by 18F-NaF PET/CT.
Methods
This is a pre-specified exploratory analysis of a prospective clinical trial (POPSTAR, ‘Pilot Study of patients with
Oligometastases from Prostate cancer treated with
STereotactic Ablative Radiotherapy’, Universal Trial
Number U1111–1140-7563) [17]. Between April 2013
and November 2014 33 patients with oligometastic prostate cancer were enrolled with written informed consent.
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They received a single fraction of 20 Gy to a total of 50
metastases. All lesions in a given patient were treated
synchronously within in a single treatment course. All
patients had a 18F-NaF PET/CT at screening, and 6
months post-treatment. Patients were excluded from the
study if they had more than three metastases after PET/
CT screening. The Quality of Life including pain scores,
and disease progression for the whole cohort has previously been reported [17]. The current analysis is limited
to those patients with demonstrable bone metastases
who received the treatment protocol.
3 MBq/kg of 18F-NaF was administered by intravenous
injection followed by a 60 min uptake period. A lowdose CT acquisition was obtained first followed by the
PET acquisition. Patients were imaged from vertex to
toes on a PET/CT scanner (Discovery 690 GE Healthcare, USA). No fasting was required. Patients were encouraged to void prior to imaging.
Radiotherapy simulation CT was performed less than 2
weeks prior to radiotherapy treatment. Scans were performed on a Philips Brilliance Big Bore CT scanner with a
2 mm slice thickness at 140 kV. The gross tumour volume
(GTV) was contoured as visualised on the 18F-NaF PET
and planning CT imaging, limited to bone. For nonverterbral metastases, an isotropic 5 mm planning target
volume (PTV) margin was applied to the GTV to account
for geometric uncertainties in the treatment. In the case of
vertebral metastases, a clinical target volume (CTV) was
applied according to the International Spine Radiosurgery
Consortium consensus guidelines [18]. A 2–3 mm PTV
margin was then applied to the CTV. Treatment planning
was performed in the Eclipse treatment planning system
(v11, Varian Medical Systems, Palo Alto, USA). Nonvertebral targets were treated with 3D conformal treatment plans which consisted of 7–9 beams typically including 1–2 non-coplanar beams. Dose was prescribed such
that at least 99% of the PTV received 20 Gy, with a maximum dose between 125 and 140%. Vertebral targets were
treated with a 9–12 coplanar IMRT fields, and prescribed
such that at least 80% of the PTV received 18 Gy, with a
maximum dose between 125 and 140%. Dose was calculated with the AAA algorithm at 2.5 mm resolution for
non-vertebral targets and 1.5 mm resolution for vertebral
targets. Radiotherapy was delivered on a Varian 21iX or
Varian TrueBeam STx linear accelerator. Patients were
immobilised in a vacuum immobilisation bag. Image guidance was performed using cone-beam CT (CBCT) and/or
Exactrac planar x-ray imaging with a 0 mm tolerance for
shifts. Mid-treatment CBCT was performed to ensure patient setup accuracy during treatment.
Image response assessment

The pre-treatmentand post-treatment 18F-NaF PET/CT
scans and the radiotherapy planning CT scan with
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contours and dose grid were imported into MIM software
(v6.6, MIM software, Cleveland, USA). The CT components of the 18F-NaF PET/CT scans were registered to the
planning CT scan. An initial rigid registration was performed on the whole CT data set. This was further refined
by rigid registration using a bounding box approximately
5 × 5 × 5 cm surrounding the GTV. This was manually adjusted if required to ensure accurate registration at the
bone target. This rigid registration was then applied to the
PET component of the 18F-NaF PET/CT scan.
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mean SUV after SABR was computed for proximal bone
receiving each of the dose levels as [SUVpost – SUVpre] /
SUVpre. The change in SUVmean in the non-tumour bone
was reviewed for all patients with bone fractures post
treatment (CTCAE v4.0).

The SUVmax was determined for the GTV contour from
the pre- and post-treatment 18F-NaF PET data. The difference in SUVmax from pre- to post-treatment was calculated as a percentage of the pre-treatment SUVmax.

Results
Twenty-one patients from the patient population with bone
metastases were included in this analysis. A total of 33 bone
lesions were irradiated (Additional file 1: Table S1). The
baseline SUV characteristics of the lesions is shown in Additional file 2: Table S2. The mean (± 1 st. dev.) time of posttherapy PET was 7.4 ± 1.0 months. The SUVmean of normal,
un-irradiated bone was consistent between pre and posttreatment scans, with a mean ratio, post/pre of 0.98 ± 0.08.
In this cohort, 18F-NaF had detected an additional 14 metastases, over that detected with CT and bone scan.

Normal bone response

SUVmax differences in tumour

The bone was contoured on the axial slices from 2 cm
above to 2 cm below the PTV using a threshold of 120
HU followed by manual correction. An isotropic 2 cm
margin was applied to the PTV and the intersection of this
and the bone contour was derived to result in a proximal
bone (bone within 2 cm of the target). This ensured the
bone contour included only the bone that was accurately
registered between the three scans. The GTV was subtracted from the proximal bone contour to obtain proximal non-tumour bone. The radiotherapy isodose lines at
2 Gy intervals were converted into contours. These were
subtracted from each other, and Boolean intersection with
the proximal non-tumour bone was performed to result in
contours covering proximal non-tumour bone receiving
each 2 Gy dose interval up to 24 Gy. The mean, median,
maximum and standard deviation in non-tumour bone receiving each dose interval was extracted. The change in

The SUVmax was computed in the GTV contour on pre
and post treatment 18F-NaF PET scans. Figure 1 shows
for an example patient the maximum intensity projection of the pre and post-SABR 18F-NaF PET images with
the planned isodose lines. Figure 2 shows a waterfall plot
of the relative change in SUVmax after SABR. Reduction
in tumour SUVmax was observed in 29/33 lesions. The
mean absolute decrease in SUVmax after SABR was 17.7
(95% CI − 25.8 to − 9.4, p = 0.0001). Increase in SUVmax
at 6 months was observed in three of 33 lesions treated
with SABR; of these, two were from the same patient.
Figure 3 shows the three lesions with increased SUVmax.
Patient 18 had T4 and L2 lesions that were determined
to be a local progression based on follow up with CT
and PSMA PET imaging at 20 months post treatment.
Specifically for the T4 lesion, full coverage of the GTV
with the prescription dose was not achieved due to the

Tumour response

Fig. 1 MIP of pre-treatment NaF PET (left) and post-treatment NaF PET for Patient 31. The planned isodose lines from are shown
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Fig. 2 a Waterfall plot of the change in SUVmax of the GTV after SABR and (b) absolute SUVmax before and after SABR

proximity of the spinal cord, which was a dose-limiting
structure. In addition, a grade 3 fracture was also observed at 18 months post treatment at L2. In the case of
a right rib lesion in patient 3, local control based on repeat CT and PSMA PET was achieved; however a grade
2 fracture was observed at 24 months post SABR.

Non-tumour bone

The change in SUVmean in the non-GTV bone receiving
each dose level from 0 Gy to 24 Gy was computed. Figure 4
shows the average change in SUVmean for the non-tumour
bone surrounding 33 targets as a function of dose. The
mean percentage reduction in the non-tumour bone

Fig. 3 Pre and post-treatment NaF scans for the two patients (three lesions) with increased SUVmax in the tumour. The tumour is shown by the
green contour, the PTV in blue and the volume receiving 20 Gy in orange. The spinal cord is shown in yellow for Patient 18
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Fig. 4 Mean change in SUVmean in non-GTV bone for the population
of patients. The uncertainty bars represent ±1 standard deviation

reduced with increasing dose, with a mean reduction of
23.3% for non-tumour bone receiving 24 Gy. Figure 5
shows a representative patient (Patient 10) treated for a
right ilium metastasis. Reduction in the tumour uptake is
observed, as is reduction in the surrounding bone uptake
in particular at the 16–20 Gy dose range.
In three patients, markedly higher 18F-NaF uptake in the
low dose area of non-tumour bone was observed. In
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Patient 6, although there was significant reduction in uptake in the treated area, increased uptake in the contiguous bone immediately adjacent to the treated volume was
observed. Similarly for Patient 4, increased uptake was observed post-treatment immediately adjacent to the treated
volume. These were both determined to be marginal recurrence. The pre and post-treatment scans for these two
patients are shown in Fig. 6. The third patient with increase in SUV adjacent to the treated volume (Patient 18,
R Acetabulum), had subsequent CT imaging which
showed stable morphology and PSMA PET negativity.
Two patients had grade 2 fractures (Patient 3: Right
Rib and Patient 20: Left Rib) and one patient had a grade
3 fracture (Patient 18, L2 Vertebra). The lesions for Patient 3 and Patient 18 did not show response to treatment at 6 months on the 18F-NaF.

Discussion
The POPSTAR trial was a prospective evaluation of
SABR for oligometastases from prostate cancer and involved high, single fraction doses to bone and lymph
node metastases [17]. This is the first study to demonstrate 18F-NaF as a response assessment tool in the
context of SABR to bone metastases. 18F-NaF provides
high spatial resolution and high sensitivity/specificity

Fig. 5 Pre and post-treatment images for Patient 10, Rt Illium. GTV is shown in red, and isodose lines in 2 Gy increments from 4 Gy to 20 Gy are
shown various colours. Reduction in the tumour uptake post-treatment is observed, as well as reduction in the non-tumour bone irradiated in
particular in the 16–20 Gy region

Hardcastle et al. Radiation Oncology

(2019) 14:164

Page 6 of 8

Fig. 6 Comparison of (left) baseline and (right) follow-up PET scan of two patients with marginal recurrence. The PTV is shown in blue, and region
treated to the prescription dose of 20 Gy is shown in orange. Increased uptake immediately adjacent to the irradiated region is highlighted

measurement of bone metastases and is representative
of osteoblastic activity and blood flow. In the current
study we have demonstrated that a single high dose fraction of external beam radiotherapy reduces 18F-NaF uptake in bone at 6 months, thus can be considered to
reduce osteoblastic activity in bone metastases in the
majority of patients. We have also shown a reduction of
osteoblastic activity in regions of non-tumour bone
treated to high doses per fraction. Bone fracture remains
a side effect in SABR to bone lesions, with two Grade 2
and one Grade 3 fractures observed in the POPSTAR
trial. In all the patients that had bone fracture postSABR, there was high residual NaF uptake within the
treated field, or there was new uptake adjacent to the
treated volume as visualised on the follow up 18F-NaF
PET scan. As reported previously for this cohort, for the
bone metastasis-specific Quality of Life module (EORTC
QLQ-BM22), painful sites, pain characteristics, and
functional interference increased from baseline only at
the 24-mo timepoint [17].
In the POPSTAR trial, bone metastasis was defined
using a combination of CT and 18F-NaF scan information.
The primary tumour was delineated by an experienced radiation oncologist and a 5 mm margin was applied to account for geometric uncertainty in the treatment delivery
(planning target volume, [PTV]). In the subset of vertebral
tumours, a CTV was applied according to international

consensus guidelines, with a 2 mm CTV-PTV expansion.
The use of 18F-NaF PET in the current study however has
shown the potential inadequacy of direct expansion to
PTV in non-vertebral bone without a CTV margin. Three
patients had regions of increased uptake immediately adjacent to the treated volume, suggesting marginal failure.
This may be mitigated by the use of a CTV margin for all
bone metastases, similar to the international consensus
guidelines for spine metastases. Despite the inclusion of a
CTV in vertebral targets, there are still limitations with
full coverage of the GTV due to the close proximity of
dose limiting structures such as the spinal cord.
In more recent years, 18F-Fluoromethylcholine has been
used for directing SABR to prostate cancer metastase, with
some prognostic value [19]. Prostate specific membrane
antigen (PSMA) PET scanning has however become the
scanning modality of choice for prostate cancer in the
metastatic setting [20]. PSMA PET has been shown to have
comparable sensitivity and specificity as 18F-NaF PET for
bone metastases in one study [21], however Uprimny et al.
[22] found 18F-NaF PET detected more skeletal metastases
and had a higher tumour to background ratio than PSMA
PET. PSMA PET has the additional advantage of visualising soft-tissue metastases, however is limited to prostate
cancer and renal cell carcinoma [23]. 18F-NaF PET thus
has a role in response assessment for skeletal metastases in
both prostate and non-prostate cancer.
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Conclusion
In this study we have shown the response to a high dose
single fraction SABR treatment to prostate bone oligometastases as visualised on 18F-NaF PET/CT. In the majority of patients, SABR reduces 18F-NaF PET/CT
uptake in the tumour, and in high dose regions reduces
uptake in non-tumour bone. Regions of increased uptake
immediately adjacent to treated volumes suggest that increased clinical target volumes are required in the treatment of bone metastases with SABR.
Additional files
Additional file 1: Table S1. Baseline characteristics of the patients
included in this study. These are only the patients that had bone
metastases. (DOCX 27 kb)
Additional file 2: Table S2. Individual lesion characteristics. Noncontiguous patient numbering is used as we are describing the bone
metastases only, rather than all metastases treated in this clinical trial.
(DOCX 17 kb)
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